血浆组织蛋白酶D活性与超重和肥胖人群肝脏胰岛素敏感性负相关
该研究基于两项大型临床试验的94名超重和肥胖成人,采用高胰岛素-正常血糖钳夹技术评估肝脏和外周胰岛素敏感性。二次分析显示血浆CTSD活性与肝脏胰岛素敏感性独立负相关,但与外周胰岛素敏感性无关,提示其或可作为无创标志物。
要点
- 血浆CTSD活性与肝脏胰岛素敏感性独立负相关(标准化β=-0.206,p=0.043)。
- CTSD活性与外周胰岛素敏感性无显著关联。
- CTSD水平与促炎因子IL-8和TNF-α正相关。
核心结论
- 血浆CTSD活性而非全身炎症与肝脏胰岛素敏感性呈负相关,提示其可能作为无创标志物。
研究设计与样本
- 基于两项大型临床试验的二次分析,纳入94名超重和肥胖成人(BMI 25-35 kg/m2),采用两步高胰岛素-正常血糖钳夹评估胰岛素敏感性。
主要发现
- 血浆CTSD水平与IL-8正相关(标准化β=0.495,p<0.001),与TNF-α正相关(标准化β=0.264,p=0.012)。
- 血浆CTSD活性与肝脏胰岛素敏感性负相关(标准化β=-0.206,p=0.043),独立于年龄、性别、BMI和腰围。
- 血浆CTSD活性与外周胰岛素敏感性无显著关联。
- 血浆IL-8和TNF-α与肝脏胰岛素敏感性无显著相关。
临床怎么用
- 血浆CTSD活性或可作为评估肝脏胰岛素敏感性的无创标志物,辅助识别肝脏胰岛素抵抗个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Insulin resistance in skeletal muscle and liver plays a major role in the pathophysiology of type 2 diabetes. The hyperinsulinaemic-euglycaemic clamp is considered the gold standard for assessing peripheral and hepatic insulin sensitivity, yet it is a costly and labour-intensive procedure. Therefore, easy-to-measure, cost-effective approaches to determine insulin sensitivity are needed to enable organ-specific interventions. Recently, evidence emerged that plasma cathepsin D (CTSD) is associated with insulin sensitivity and hepatic inflammation. Here, we aimed to investigate whether plasma CTSD is associated with hepatic and/or peripheral insulin sensitivity in humans. METHODS: As part of two large clinical trials (one designed to investigate the effects of antibiotics, and the other to investigate polyphenol supplementation, on insulin sensitivity), 94 overweight and obese adults (BMI 25-35 kg/m2) previously underwent a two-step hyperinsulinaemic-euglycaemic clamp (using [6,6-2H2]glucose) to assess hepatic and peripheral insulin sensitivity (per cent suppression of endogenous glucose output during the low-insulin-infusion step, and the rate of glucose disappearance during high-insulin infusion [40 mU/(m2 × min)], respectively). In this secondary analysis, plasma CTSD levels, CTSD activity and plasma inflammatory cytokines were measured. RESULTS: Plasma CTSD levels were positively associated with the proinflammatory cytokines IL-8 and TNF-α (IL-8: standardised β = 0.495, p < 0.001; TNF-α: standardised β = 0.264, p = 0.012). Plasma CTSD activity was negatively associated with hepatic insulin sensitivity (standardised β = -0.206, p = 0.043), independent of age, sex, BMI and waist circumference, but it was not associated with peripheral insulin sensitivity. However, plasma IL-8 and TNF-α were not significantly correlated with hepatic insulin sensitivity. CONCLUSIONS/INTERPRETATION: We demonstrate that plasma CTSD activity, but not systemic inflammation, is inversely related to hepatic insulin sensitivity, suggesting that plasma CTSD activity may be used as a non-invasive marker for hepatic insulin sensitivity in humans.
引用
- Ding L, Goossens GH, Oligschlaeger Y, et al. Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans. Diabetologia. 2019. PMID: 31690989. doi:10.1007/s00125-019-05025-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。